# Oxaliplatin combined with capecitabine therapy and comprehensive nursing in advanced colorectal cancer patients

**Authors:** Dan Kuang, Hong Xu, Xiaoming Shen

PMC · DOI: 10.3389/fmed.2025.1582683 · Frontiers in Medicine · 2025-07-02

## TL;DR

This study shows that combining oxaliplatin with capecitabine and comprehensive nursing improves outcomes for advanced colorectal cancer patients.

## Contribution

The study demonstrates the added benefits of oxaliplatin and comprehensive nursing in advanced CRC treatment.

## Key findings

- The research group had a higher total effective rate and better immune function compared to the control group.
- Patients in the research group showed improved quality of life and lower anxiety and depression scores.
- The research group had a better long-term survival rate after 2 years of follow-up.

## Abstract

This study aimed to discuss the influence of oxaliplatin combined with capecitabine therapy and comprehensive nursing in advanced colorectal cancer (CRC) patients.

A total of 100 advanced CRC patients, selected from January 2019 to January 2021, were divided into a control group (CG) and a research group (RG). Patients in the CG received capecitabine tablets and underwent routine nursing, while those in the RG received capecitabine tablets along with intravenous infusion of oxaliplatin and underwent comprehensive nursing. The short-term effects, levels of tumor markers, immune function, quality of life, occurrence of adverse reactions, negative emotions, and long-term survival rate in both groups were compared.

In comparison to the CG, the RG exhibited a higher total effective rate (p < 0.05), lower cancer antigen 125 (CA125) and carbohydrate-associated antigen 199 (CA199) levels (p < 0.05), higher CD4+ and CD4+/CD8+ levels (p < 0.05), a higher Karnofsky performance status (KPS) score, a lower occurrence of adverse reactions (p < 0.05), lower Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) scores (p < 0.05), and a better long-term survival rate of patients after 2 years of follow-up (p < 0.05).

Oxaliplatin combined with capecitabine therapy, with comprehensive nursing, can effectively reduce clinical symptoms, enhance the immune function, and improve the quality of life of advanced CRC patients.

## Linked entities

- **Chemicals:** oxaliplatin (PubChem CID 9887053), capecitabine (PubChem CID 60953)
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** MUC16 (mucin 16, cell surface associated) [NCBI Gene 94025] {aka CA125}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** tumor (MESH:D009369), Anxiety (MESH:D001007), Depression (MESH:D003866), CRC (MESH:D015179)
- **Chemicals:** Oxaliplatin (MESH:D000077150), capecitabine (MESH:D000069287)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12263592/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12263592/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12263592/full.md

---
Source: https://tomesphere.com/paper/PMC12263592